e-learning
resources
Paris 2018
Sunday, 16.09.2018
Asthma management
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Exposure-response analysis of tezepelumab in patients with severe asthma to guide phase 3 dose selection
N. Ly (Mountain View, United States of America), Y. Zheng (Mountain View, United States of America), J. Griffiths (Gaithersburg, United States of America), R. Van Der Merwe (Cambridge, United Kingdom), B. Agoram (Mountain View, United States of America), L. Roskos (Gaithersburg, United States of America)
Source:
International Congress 2018 – Asthma management
Session:
Asthma management
Session type:
Poster Discussion
Number:
1688
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Ly (Mountain View, United States of America), Y. Zheng (Mountain View, United States of America), J. Griffiths (Gaithersburg, United States of America), R. Van Der Merwe (Cambridge, United Kingdom), B. Agoram (Mountain View, United States of America), L. Roskos (Gaithersburg, United States of America). Exposure-response analysis of tezepelumab in patients with severe asthma to guide phase 3 dose selection. 1688
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Population pharmacokinetic and exposure-response analyses to support fixed dosing of tezepelumab in patients with severe asthma
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
Effect of high or low-medium accumulated dose regimes of systemic corticosteroids for hospitalised patients with exacerbated chronic obstructive pulmonary disease: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials
Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data
Year: 2021
Factors affecting patients’ decision to adjust treatment; secondary analysis of a randomised trial of treatment optimisation in patients with severe asthma
Source: Virtual Congress 2021 – Asthma burden and management I
Year: 2021
Decaf score for predicting treatment escalation in exacerbations of COPD
Source: Virtual Congress 2020 – Clinical and functional evaluation of COPD
Year: 2020
Reslizumab for uncontrolled eosinophilic asthma in patients who experienced a single exacerbation in the previous year: sub-analysis of two phase 3 trials
Source: International Congress 2017 – Asthma management
Year: 2017
COPD exacerbations in the phase 3 revefenacin clinical trial program
Source: International Congress 2018 – Clinical trials in COPD: new results
Year: 2018
A realistic study assessing inhaled treatment compliance in COPD patients
Source: Eur Respir J 2001; 18: Suppl. 33, 25s
Year: 2001
Relationship between change in trough FEV1 and COPD patient outcomes: Pooled analysis of 23 clinical trials in patients with COPD
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
Latent class analyses used to study phenotypes in severe COPD with exacerbation. A pilot study
Source: Annual Congress 2010 - Epidemiological data for smoking control
Year: 2010
Pooled analyses of five phase 2b studies support dose selection of glycopyrrolate-formoterol (GFF) MDI (PT003) 18/9.6 μg for phase III development
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013
Effect of high extrafine strength (HS) ICS-containing triple therapy on exacerbations in patients with severe asthma and persistent airflow limitation: Post-hoc analysis of the TRIGGER study
Source: International Congress 2019 – Novel findings from asthma clinical trials
Year: 2019
Persistence of clinical criteria of chronic bronchitis in patients with COPD over time: A longitudinal analysis of the TRACE cohort.
Source: International Congress 2017 – Markers of COPD progression
Year: 2017
Small airways function: evaluation in a population of adult patients with severe asthma and potential use as a response biomarker for anti-IL5 therapy
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
COPD in the time of COVID-19: an analysis of acute exacerbations and reported behavioural changes in patients with COPD
Source: ERJ Open Res, 7 (1) 00718-2020; 10.1183/23120541.00718-2020
Year: 2021
Adding montelukast versus doubling the budesonide dose in persistent asthma: a subgroup analysis of the COMPACT study
Source: Eur Respir J 2002; 20: Suppl. 38, 388s
Year: 2002
Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021
Early occurrence of any COPD exacerbation predicts further higher risk of moderate/severe exacerbations regardless of recording tool: the FLAME study
Source: International Congress 2017 – Management of COPD
Year: 2017
A new treatment algorithm for acute exacerbation of IPF: a retrospective cohort study.
Source: International Congress 2019 – Recent developments in intensive care unit medicine
Year: 2019
Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis
Source: Eur Respir J, 56 (4) 2000151; 10.1183/13993003.00151-2020
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept